H

Hualan Biological Bacterin Inc
SZSE:301207

Watchlist Manager
Hualan Biological Bacterin Inc
SZSE:301207
Watchlist
Price: 18.08 CNY -2.01% Market Closed
Market Cap: 10.9B CNY
Have any thoughts about
Hualan Biological Bacterin Inc?
Write Note
Hualan Biological Bacterin Inc
/
Income Statement
/
Net Income (Common)

Hualan Biological Bacterin Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hualan Biological Bacterin Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
H
Hualan Biological Bacterin Inc
SZSE:301207
Net Income (Common)
¥860m
CAGR 3-Years
-2%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-¥6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Net Income (Common)
-¥1.3B
CAGR 3-Years
3%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
¥1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
¥3.7B
CAGR 3-Years
-26%
CAGR 5-Years
12%
CAGR 10-Years
39%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
¥1.9B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

Hualan Biological Bacterin Inc
Glance View

Market Cap
10.8B CNY
Industry
Biotechnology

In the bustling landscape of biotechnology, Hualan Biological Bacterin Inc. emerges as a formidable player. This Chinese company, rooted in the province of Henan, has carved its niche in the development and manufacture of human vaccines. Hualan's journey began with a focused vision on advancing public health through immunization. Today, it stands among the largest producers of human vaccines in China, adeptly navigating the stringent regulatory environments that govern this critical sector. The company's innovative approach in vaccine research is bolstered by state-of-the-art facilities and an unwavering commitment to quality, enabling it to produce safe, effective, and affordable vaccines. Over the years, Hualan has expanded its portfolio to include vaccines for influenza, rabies, and measles, to name a few, each product carefully developed to meet domestic and international health needs. Hualan Biological Bacterin Inc. generates its revenues substantially through the sale of these vaccines. The company's business model leans heavily on its strong distribution network, which ensures that its products effectively reach healthcare providers and institutions across China. Regulatory approvals for new vaccines further pave the way for market expansion and potential export opportunities, contributing to revenue growth. Furthermore, the company strategically invests in research and development, consistently working on new immunological breakthroughs, thus securing its standing and paving the way for future revenue streams. Through this meticulous combination of development, regulatory savvy, and strategic distribution, Hualan not only sustains its financial health but continues to play a vital role in advancing global public health.

Intrinsic Value
30.95 CNY
Undervaluation 42%
Intrinsic Value
Price
H
What is Intrinsic Value?

See Also

What is Hualan Biological Bacterin Inc's Net Income (Common)?
Net Income (Common)
860m CNY

Based on the financial report for Dec 31, 2023, Hualan Biological Bacterin Inc's Net Income (Common) amounts to 860m CNY.

What is Hualan Biological Bacterin Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
26%

Over the last year, the Net Income (Common) growth was 65%. The average annual Net Income (Common) growth rates for Hualan Biological Bacterin Inc have been -2% over the past three years , 26% over the past five years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.